期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

健择联合奥沙利铂治疗老年中晚期非小细胞肺癌的临床研究 被引量：1

下载PDF
导出
摘要 目的观察健择联合奥沙利铂治疗老年中晚期非小细胞肺癌的临床疗效及毒副反应。方法50例老年中晚期非小细胞肺癌采用健择、奥沙利铂联合方案化疗:健择1000mg/m2静脉滴注,d1,8,奥沙利铂100mg/m2静脉滴注,d1,21d为1周期。采用WHO疗效及毒副反应评价标准,完成治疗2个周期以上的患者进行临床疗效及毒副反应评估。结果可评价疗效50例,有效(RR)率42%(21/50),其中完全缓解(CR)5例,部分缓解(PR)16例,稳定(SD)23例,进展(PD)6例。缓解期为1.5～12个月,中位缓解期为7个月。生存期为4～19个月,中位生存期为10个月,1年生存率48%(24/50)。50例共化疗121个周期,主要毒副反应为骨髓抑制9例(18%)、贫血6例(12%)、血小板减少7例(14%);非血液毒性反应较轻,主要表现为胃肠道反应7例(14%)。结论健择联合奥沙利铂方案治疗老年中晚期非小细胞肺癌的疗效较好,毒副反应较轻,患者的耐受性好。
作者 王海存 程鹏
机构地区 南阳医学高等专科学校第一附属医院肿瘤内科Ⅰ
出处 《肿瘤基础与临床》 2009年第1期76-77,共2页 journal of basic and clinical oncology
关键词 非小细胞肺癌 老年人 化学治疗 健择 奥沙利铂
分类号 R734.2 [医药卫生—肿瘤]
  • 相关文献

参考文献8

  • 1Isobe T, Herbst RS, Onn A. Current management of abvanced non- small cell lung cancer: targeted therapy [ J]. Semin Oncol, 2005, 32 (3) :315 -328.
  • 2Milton DT, Miller VA. Advances in cytotoxic chemotherapy for the treatment of metastatic or recurent non-small cell lung cancer [ J ]. Semin Oncol, 2005, 32(3): 299-314.
  • 3Cho LC, Do, cell JE, Garwoon D, et al. Prophylactic cranial irradia- tion with combined modality therapy for patients with locally advanced non-small cell lung cancer [ J ]. Semin Oncol, 2005,32 ( 3 ) : 293 - 298.
  • 4Parente B, Barroso A, Conde S, et al. A prospective study of gemcitabine and garboplatin as first-line therapy in advanced non-small cell lung cancer: toxicity of a three-versus a fourweek schedule[ J]. Serain Oncol,2001,28 (3 Suppl 10) : 10 - 14.
  • 5Domine M, Casado V, Estevez LG, et al. Gemcitabin and carboplatin for patients with advanced non-small cell lung cancer[ J]. Semin Oncol, 2001, 28 (3 Suppl 10): 429.
  • 6Schiller JH, Harrington D, Sandier A, et al. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer [ J ]. N Engl J Med, 2002, 346(2) : 92 -98.
  • 7Sundstrom S, Bremnes RM, Kaasa S, et al. Second-line chemothera- py in recurrent small cell lung cancer. Results from a crossover schedule after primary treatment with cisplatinand etoposide (EP-regimen) or cyclophosphamide, epirubicin and vincristin (CEV-regimen) [ J]. Lung Cancer, 2005, 48(2) :251 -261.
  • 8Kaira TA, Takise A, Minato K, et al. Phase Ⅱ study of weekly docetaxel and cisplatin in patients with non-small call lung cancer[ J]. Anticancer Drugs, 2005,16 ( 4 ) :455 - 460.

同被引文献11

  • 1陈永锋,杨和平,胡建林,周向东,熊玮,戴晓天,李学军.健择联合奥沙利铂治疗非小细胞肺癌临床疗效分析[J].西南国防医药,2007,17(2):212-214. 被引量：1
  • 2Symmans WF,Volm MD,Shapiro RL,et al.Paclitaxel induced apoptosis and mitotic arrest assessed by serial fine needle aspiration:implication for early prediction of breast cancer response to neoadjuvant treatment[J].Clin Cancer Res,2000,6(12):4610-4617.
  • 3Srivastava RK,Sasaki CY,Hardwick JM,et al.Bcl-2 mediated drug resistance:Inhibition of apetosis by blocking muclear factor of activated T lymphocytes(NFAT)-NDUCED Fas ligand transcription[J].J Exp Med,1999,190(2):253-265.
  • 4Essmann F,Wieder T,Otto A,et al.GDP dissociation inhibitor D4GDI(Rbo-DI 2),but not the homologous rho GDI 1,is cleaved by caspase-3 during drug induced apoptosis[J].Biochem J,2000,346(3):777-783.
  • 5Ling YH,Consoli U,Tornos C,et al.Accumulation of cyclin B1,acti vation of cyclin B1 dependent kinase and induction of programmed cell death in human epidermoid carcinoma KB cells treated with taxol[J].Int J cancer,1998,75(6):925-932.
  • 6Frances A.Chemotherapy for non small cell lung callcer:have we reached a new plateau[J].Semin Onco,1999,26(1):3-11.
  • 7Domine M,Casado V,EstevezLG,et al.Gemcitabine and carbopltin for patients with advanced non-small cell lung cancer[J].Smin Oncol,2001,28(3):4.
  • 8Baggstrom M Q,Stinchcomebe T E,Fried D B,et al.Third-eneration chemotherapy agents in the treatmentofadvanced non-small cell lung:a meta-analysis[J].J Thorac Onco,2007,2(9):845.
  • 9周济昌.抗癌药物的临床应用[M].北京:化学工业出版社,2001.85-86.
  • 10管忠震,陈茹琴,徐光川,李宇红,许立功,李龙云,刘叙仪,廖美琳,李金瀚.Gemcitabine治疗晚期非小细胞肺癌的临床研究[J].癌症,1999,18(3):241-245. 被引量：177

引证文献1

肿瘤基础与临床
2009年 第1期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部